Status:
COMPLETED
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Unspecified Childhood Solid Tumor, Protocol Specific
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may...
Detailed Description
OBJECTIVES: Primary * Determine the pharmacokinetics of daunorubicin hydrochloride in pediatric patients with malignancy. Secondary * Evaluate the relationship between body composition (percent bo...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of any malignancy
- Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride administered as an infusion of any duration for \< 24 hours on either a 1- or a 2-day schedule, including bolus and all short infusion schedules
- PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- No significant uncontrolled systemic illness
- Large implanted prostheses allowed (should not undergo dual energy x-ray absorptiometry scan)
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2020
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT00673257
Start Date
January 1 2007
End Date
March 31 2020
Last Update
April 14 2020
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294
2
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016-7710
3
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
4
Children's Hospital of Orange County
Orange, California, United States, 92868